1 / 3
Being supported by an advanced and expert IT crew, we provide technical support with comprehensive pre-sales and after-sales assistance for Manufacturer standard Peptides 99% Peptides Sema, Tirze, Retatrutide Weight Loss, Cagrisema, and Cagrilintide. We warmly welcome domestic and international clients to send inquiries; our dedicated workforce operates 24 hours a day to remain your trusted global partner.
Standard China Cagrilintide and Tirze supply: We take pride in delivering products globally with flexible, rapid, and efficient services alongside rigorous quality control standards that have consistently earned customer acclaim.
Retatrutide works in the treatment of obesity by targeting three different hunger-regulating hormones:
– GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone released from the gut after eating. Retatrutide stimulates beta-cells in the pancreas to secrete insulin. The drug is a peptide formulated with a specific amino acid sequence, acting as a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors. It has demonstrated clinical efficacy in achieving a mean weight reduction exceeding 24% in non-diabetic obese or overweight adults.
Retatrutide is administered as a once-weekly injection that influences metabolic hunger signaling, prompting early satiety and reduced appetite—comparable in routine to Ozempic, Wegovy, and Mounjaro.
Unlike Ozempic and Wegovy (which mimic only GLP-1) or Mounjaro (which targets GLP-1 and GIP), retatrutide represents a single molecule addressing three pathways simultaneously: GLP-1, GIP, and glucagon. This comprehensive action delivers notably stronger appetite suppression and dietary satisfaction.
In the clinical trial published in the New England Journal of Medicine (NEJM), participants with obesity receiving the highest weekly dose of retatrutide (12 mg) achieved an average weight loss of 58 pounds over an 11-month timeframe. Weight trajectories continued downward at the trial's conclusion, showing potential for extended therapeutic benefit. Notably, 100% of participants on the 12 mg dose shed at least 5% of their total body weight, while 25% lost 30% or more.
Additionally, a study documented in The Lancet targeting individuals with Type 2 diabetes reported an approximate 17% bodyweight decrease over nine months—a substantial outcome given the conventional physiological challenges of achieving significant weight reduction within diabetic profiles.
